In Focus
Including societal and economic benefits in vaccine health technology assessments
To gain approval for use in the NHS, vaccines must undergo health technology assessments that are based primarily on clinical outcomes and costs to the healthcare sector. Some argue that this approach undervalues vaccines and that broader socioeconomic benefits, such as gains in productivity and educational attainment, should be considered in all assessments. Critics of this proposal point to a range of ethical, practical and methodological challenges.